Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.40 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.40 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20916549 | 0.87 | GAA (0.43) | HRH4PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL20916541 | 0.74 | SPR (0.35) | KCNH2SLC6A2SLC6A4SLC6A3KMT2A | |
| SCHEMBL20916519 | 0.72 | BTK (0.37) | — | |
| SCHEMBL20916518 | 0.71 | BTK (0.36) | — | |
| SCHEMBL20916643 | 0.71 | GAA (0.42) | HRH4PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL20916543 | 0.71 | JAK2 (0.37) | — | |
| SCHEMBL20916570 | 0.71 | BTK (0.38) | — | |
| SCHEMBL20916575 | 0.69 | BTK (0.34) | MAPT | |
| SCHEMBL20916686 | 0.68 | MAP4K4 (0.34) | — | |
| SCHEMBL20916560 | 0.68 | MAP4K4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793551-B2 | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 | Effector Therapeutics Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10793551-B2 | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 | Effector Therapeutics Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| EP-3697777-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | eFFECTOR Therapeutics, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| WO-2019079369-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20190119256-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (JP) | 2019-04-25 | — | — | US | disclosed |
| US-20190119256-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (JP) | 2019-04-25 | — | — | US | disclosed |
| WO-2019079369-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119256-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | NEK5, MINK1, NIM1K | HRH4 490/4885KCNH2 1750/4885DRD2 3650/4885 |
| US-10793551-B2 | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 | NEK5, MINK1, NIM1K | HRH4 490/4885KCNH2 1750/4885DRD2 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.